TrialCell reports. Medicine2025

Phase 1/2 trial of brogidirsen: Dual-targeting antisense oligonucleotides for exon 44 skipping in Duchenne muscular dystrophy.

Hirofumi Komaki et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.